Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A multicenter, open-label, phase 1 clinical trial of AJ1-11095 administered as oral monotherapy in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have been failed by a type I JAK2 inhibitor (JAK2i)
    Meeting Abstract

    Mascarenhas, J. O.; Borate, U.; Bose, P.; Byrd, J. C.; Garcia, J. S.; Grunwald, M. R.; Hobbs, G. S.; Hoffman, R.; Kuykendall, A. T.; Mesa, R. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Analysis of mouse model and development of a novel immunotherapy in myeloid malignancies
    Meeting Abstract

    Fujino, T.; Daniyan, A. F.; Abdel-Wahab, O.; Kitamura, T.
    Cancer Science (2024)

    Fulltext@MSK | Save
  • POIESIS: A randomized, double-blind, placebo-controlled, multicenter, global phase 3 study of navtemadlin as add-on to ruxolitinib in JAK inhibitor-naive patients with myelofibrosis who have a suboptimal response to ruxolitinib
    Meeting Abstract

    Vachhani, P.; Rampal, R.; Bradley, T.; Harrison, C.; Jain, T.; Kuykendall, A. T.; Palandri, F.; Mascarenhas, J. O.; Al-Ali, H. K.; Passamonti, F.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Trial in progress: An open-label clinical trial of RVU120 as monotherapy and in combination with ruxolitinib in patients with intermediate or high-risk, primary or secondary myelofibrosis (POTAMI-61)
    Meeting Abstract

    Kuklik, R.; Falkowski, A.; Zaroogian, Z.; Mazan, M.; Szymula, A.; Wilkinson, G.; Adamczyk, E.; Woznicki, J.; Micek, M.; Coelho, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-word effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia
    Meeting Abstract

    Rampal, R.; Marrone, M.; Morere, L.; Oladapo, A.; Suthar, P.; Sura, T.; Vasudevan, A.; Vredenburg, M.; Zeng, J.; Mascarenhas, J. O.
    Blood (2024)

    Fulltext@MSK | Save
  • Early anemia response in patients with myelofibrosis treated with pacritinib in real-word clinical settings
    Meeting Abstract

    Mascarenhas, J. O.; Marrone, M.; Morere, L.; Oladapo, A.; Suthar, P.; Sura, T.; Vasudevan, A.; Vredenburg, M.; Zeng, J.; Rampal, R.
    Blood (2024)

    Fulltext@MSK | Save
  • Novel nilotinib tablet formulation: Pharmacokinetic characterization and effects of food
    Meeting Abstract

    Mauro, M. J.; Radich, J. P.; Jain, P.; Sequeira, D.; Douer, D.
    Blood (2024)

    Fulltext@MSK | Save
  • River-52: A multicenter, open-label clinical trial of RVU120 in patients with relapsed or refractory high-risk myelodysplastic syndrome or acute myeloid leukemia
    Meeting Abstract

    Papayannidis, C.; Madry, K.; Centkowski, P.; Prejzner, W.; Butrym, A.; Chraniuk, D.; Saba, C.; Angelosanto, N.; Curley, R.; Nogai, H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1/2 study of nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, in combination with JAK inhibitors ruxolitinib or momelotinib in patients with myelofibrosis
    Meeting Abstract

    Mascarenhas, J. O.; Rampal, R.; El Chaer, F.; Gupta, V.; Shimoda, K.; Kiladjian, J. J.; Passamonti, F.; Bose, P.; Scandura, J. M.; Mesa, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • US expert consensus on defining intolerance to tyrosine kinase inhibitor treatment in chronic phase chronic myeloid leukemia (CML)
    Meeting Abstract

    Atallah, E. L.; Broder, M. S.; Chan, O.; Dalglish, H.; Flynn, K. E.; Gilreath, J.; Hine, M.; Hunter, A. M.; Mauro, M. J.; Pinilla-Ibarz, J.; more...
    Blood (2024)

    Fulltext@MSK | Save